Anti-tumor effects of fibroblast growth factor-binding protein (FGF-BP) knockdown in colon carcinoma
Open Access
- 23 November 2011
- journal article
- Published by Springer Nature in Molecular Cancer
- Vol. 10 (1) , 144
Abstract
Background: Fibroblast growth factors FGF-1 and FGF-2 are often upregulated in tumors, but tightly bound to heparan sulphate proteoglycans of the extracellular matrix (ECM). One mechanism of their bioactivation relies on the FGF-binding protein (FGF-BP) which, upon reversible binding to FGF-1 or -2, leads to their release from the ECM. FGF-BP increases tumorigenicity and is highly expressed in tumors like colon carcinoma. In this paper, we analyse cellular and molecular consequences of RNAi-mediated FGF-BP knockdown in colon carcinoma, and explore the therapeutic effects of the nanoparticle-mediated delivery of small interfering RNAs (siRNAs) for FGF-BP targeting.Results: Employing stable RNAi cells, we establish a dose-dependence of cell proliferation on FGF-BP expression levels. Decreased proliferation is mirrored by alterations in cell cycle distribution and upregulation of p21, which is relevant for mediating FGF-BP effects. While inhibition of proliferation is mainly associated with reduced Akt and increased GSK3β activation, antibody array-based analyses also reveal other alterations in MAPK signalling. Additionally, we demonstrate induction of apoptosis, mediated through caspase-3/7 activation, and alterations in redox status upon FGF-BP knockdown. These effects are based on the upregulation of Bad, Bax and HIF-1α, and the downregulation of catalase. In a therapeutic FGF-BP knockdown approach based on RNAi, we employ polymer-based nanoparticles for the in vivo delivery of siRNAs into established wildtype colon carcinoma xenografts. We show that the systemic treatment of mice leads to the inhibition of tumor growth based on FGF-BP knockdown.Conclusions: FGF-BP is integrated in a complex network of cytoprotective effects, and represents a promising therapeutic target for RNAi-based knockdown approaches.Keywords
This publication has 62 references indexed in Scilit:
- Polyethylenimine/small interfering RNA‐mediated knockdown of vascular endothelial growth factor in vivo exerts anti‐tumor effects synergistically with BevacizumabThe Journal of Gene Medicine, 2010
- KLF5 Promotes Breast Cell Survival Partially through Fibroblast Growth Factor-binding Protein 1-pERK-mediated Dual Specificity MKP-1 Protein Phosphorylation and StabilizationJournal of Biological Chemistry, 2009
- A distinct role for secreted fibroblast growth factor-binding proteins in developmentProceedings of the National Academy of Sciences, 2009
- Transfection of small RNAs globally perturbs gene regulation by endogenous microRNAsNature Biotechnology, 2009
- Akt2 overexpression plays a critical role in the establishment of colorectal cancer metastasisProceedings of the National Academy of Sciences, 2008
- Akt Determines Replicative Senescence and Oxidative or Oncogenic Premature Senescence and Sensitizes Cells to Oxidative ApoptosisCancer Cell, 2008
- The impact of O2 availability on human cancerNature Reviews Cancer, 2008
- The paradoxical pro- and anti-apoptotic actions of GSK3 in the intrinsic and extrinsic apoptosis signaling pathwaysProgress in Neurobiology, 2006
- Mechanism of fibroblast growth factor-binding protein 1 repression by TGF-βBiochemical and Biophysical Research Communications, 2006
- A Tetracycline-Responsive Promoter System Reveals the Role of a Secreted Binding Protein for FGFs during the Early Phase of Tumor GrowthBiochemical and Biophysical Research Communications, 1996